Physician profile
Basma Khalil
NPI 1801135322
$2,860.26
in general payments reported to CMS, 2019-2025
24 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $343 · 2021: $587 · 2022: $772 · 2023: $485 · 2024: $194 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.89 |
| Education | $112.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $476.74 | 2020-2023 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $425.55 | 2020-2025 | Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $377.58 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $240.98 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $187.35 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $177.73 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $144.04 | 2020-2023 | Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.24 | 2021-2022 | |
| Pfizer INC. | $99.36 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $93.66 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $92.45 | 2021 | |
| Abbott Laboratories | $75.73 | 2021-2022 | |
| Amgen INC. | $65.98 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $63.27 | 2019-2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.98 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $41.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.32 | 2021 | |
| Amarin Pharma, INC. | $27.05 | 2020 | |
| Sanofi Pasteur INC. | $19.75 | 2022 | |
| Medtronic, INC. | $16.27 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.20 | 2020 | |
| Nestle Healthcare Nutrition INC. | $14.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.34 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basma Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.